Mucopolysaccharidosis type I: current knowledge on its pathophysiological mechanisms.
about
Ganglioside biochemistryNormalization and improvement of CNS deficits in mice with Hurler syndrome after long-term peripheral delivery of BBB-targeted iduronidase.Isokinetic muscle strength differences in patients with mucopolysaccharidosis I, II, and VIBrain and muscle redox imbalance elicited by acute ethylmalonic acid administration.Neurocognition across the spectrum of mucopolysaccharidosis type I: Age, severity, and treatment.Neuroinflammatory paradigms in lysosomal storage diseases.Multidisciplinary Team Approach Is Key for Managing Pregnancy and Delivery in Patient with Rare, Complex MPS IFactors and processes modulating phenotypes in neuronopathic lysosomal storage diseases.Proteomic analysis of mucopolysaccharidosis I mouse brain with two-dimensional polyacrylamide gel electrophoresis.Chiari I malformation and syringomyelia in mucopolysaccharidosis type I (Hurler syndrome) treated with posterior fossa decompression: Case report and review of the literature.An algorithm to predict phenotypic severity in mucopolysaccharidosis type I in the first month of life.MPS I - Hurler syndromeImpaired bone remodeling and its correction by combination therapy in a mouse model of mucopolysaccharidosis-I.Oral manifestations of 17 patients affected with mucopolysaccharidosis type VI.Cytogenetic biomonitoring in mucopolyssacharosis I, II and IV patients treated with enzyme replacement therapy.Getting the Most: Enhancing Efficacy by Promoting Erythropoiesis and Thrombopoiesis after Gene Therapy in Mice with Hurler Syndrome
P2860
Q35361488-875F4C97-E52A-4728-AD05-039C297C7B88Q35600316-4EF22A63-56C4-42F0-B1D2-4080BA8BA1DCQ35627722-C770B7CA-502A-4263-AB3B-8308C0CFB6BDQ35641745-29B386F7-8017-4971-9059-051BDFC6EC96Q36032860-55F56858-2691-4338-AA4C-C1CB517D098FQ36232187-27DEEFE6-594F-455E-9DE9-CC1DF2781623Q37415876-E3AF145D-13EC-4469-A759-794C90CE2088Q37595934-BC4B9799-BF43-48AD-8189-83FA4D7A146CQ38441487-1B3BA714-1EAA-4315-A7B8-0D736B97DF5EQ39368399-0B228F4B-7C95-4C63-82F7-7495506B49E8Q42122146-13108768-2B28-45E0-BFB3-B65849E1EF5EQ45316402-9CDD5EF0-D68B-407A-AA4E-1EA526567601Q45879685-41A10780-BFDF-403F-BD0F-2074CF6D4402Q45909286-EBB1335E-BB4B-4D1B-BDA5-424D0CD06BF7Q50642537-27A1061E-06F2-4351-8AF3-00D2CC1F2272Q58577240-DC1EFB3D-051B-4C44-BCDC-0705A54F1FF2
P2860
Mucopolysaccharidosis type I: current knowledge on its pathophysiological mechanisms.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Mucopolysaccharidosis type I: current knowledge on its pathophysiological mechanisms.
@en
type
label
Mucopolysaccharidosis type I: current knowledge on its pathophysiological mechanisms.
@en
prefLabel
Mucopolysaccharidosis type I: current knowledge on its pathophysiological mechanisms.
@en
P2860
P1476
Mucopolysaccharidosis type I: current knowledge on its pathophysiological mechanisms.
@en
P2093
Derbis Campos
Madelyn Monaga
P2860
P2888
P304
P356
10.1007/S11011-012-9302-1
P577
2012-04-14T00:00:00Z
P6179
1003673138